A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first or second-line therapy for advanced non-small cell lung cancer (NSCLC)
You are leaving Smmttx.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible
for
its contents.
Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.
To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first or second-line therapy for advanced non-small cell lung cancer (NSCLC)